Dolutegravir alone versus with tenofovir for HTLV-1
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Cancer, Immune system & allergy, Infections clinical trials.
This study tests whether adding tenofovir (an antiviral medication) to dolutegravir helps treat HTLV-1 infection better than dolutegravir alone. HTLV-1 is a virus that can cause serious health problems, and researchers want to find the most effective treatment combination.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have confirmed HTLV-1 infection (a blood test showing the virus)
- You have symptoms or health problems caused by HTLV-1
- You do not have HIV, hepatitis C, or hepatitis B infections
- You do not have active tuberculosis
- Your kidneys function well enough (not severely damaged)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-drug HIV treatment (dolutegravir and lamivudine) for people who also have active TB and are taking a standard TB medicine called rifampin. It is designed for those who have not yet started HIV treatment.
This study compares two HIV medicines, doravirine and dolutegravir, to see which works better for people who have never taken HIV treatment before. If you qualify, you would be randomly assigned to one of the two medications.
This trial tests whether switching (or continuing) treatment with dolutegravir (DTG) plus lamivudine (3TC) works as well and is better tolerated in adults with HIV that is already controlled. It is specifically for people who have possible kidney (TDF-related) or bone side effects from their current TDF-based regimen.
This Phase 2 study tests how well and how safely an HIV medicine (dolutegravir) works when given with rifampicin, a common anti-TB medicine, for people starting HIV treatment during TB treatment. It also studies drug levels in the body to help confirm dosing and safety while treating both infections.
This trial tests better ways to manage HIV when the virus becomes resistant to dolutegravir (DTG), a key medicine. It is for people with high viral load despite being on DTG for at least six months.
This trial studies whether taking dolutegravir plus lamivudine (a simpler two-drug regimen) can work as well as a standard three-drug HIV regimen for people who have reasons they can’t stay on the usual medicines. You may be offered free treatment if you meet the safety checks and can attend follow-up visits.
Hear when a new HTLV-1 Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.